JP2007527850A5 - - Google Patents

Download PDF

Info

Publication number
JP2007527850A5
JP2007527850A5 JP2006500159A JP2006500159A JP2007527850A5 JP 2007527850 A5 JP2007527850 A5 JP 2007527850A5 JP 2006500159 A JP2006500159 A JP 2006500159A JP 2006500159 A JP2006500159 A JP 2006500159A JP 2007527850 A5 JP2007527850 A5 JP 2007527850A5
Authority
JP
Japan
Prior art keywords
group
groups
composition
prostaglandin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006500159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527850A (ja
JP4584908B2 (ja
Filing date
Publication date
Priority claimed from FR0350023A external-priority patent/FR2850864B1/fr
Application filed filed Critical
Priority claimed from PCT/FR2004/000325 external-priority patent/WO2004073594A2/fr
Publication of JP2007527850A publication Critical patent/JP2007527850A/ja
Publication of JP2007527850A5 publication Critical patent/JP2007527850A5/ja
Application granted granted Critical
Publication of JP4584908B2 publication Critical patent/JP4584908B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006500159A 2003-02-12 2004-02-12 皮膚または皮膚付属物の色素沈着を刺激するための１５−ヒドロキシプロスタグランジンデヒドロゲナーゼの阻害剤の使用 Expired - Lifetime JP4584908B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0350023A FR2850864B1 (fr) 2003-02-12 2003-02-12 Utilisation d'un inhibiteur de 15-hydroxy prostaglandine deshydrogenase pour favoriser la pigmentation de la peau ou des phaneres
US45656303P 2003-03-24 2003-03-24
PCT/FR2004/000325 WO2004073594A2 (fr) 2003-02-12 2004-02-12 Utilisation d’un inhibiteur de 15-hydroxy prostaglandine deshydrogenase pour favoriser la pigmentation de la peau ou des phaneres

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010025811A Division JP2010100659A (ja) 2003-02-12 2010-02-08 皮膚または皮膚付属物の色素沈着を刺激するための１５−ヒドロキシプロスタグランジンデヒドロゲナーゼの阻害剤の使用

Publications (3)

Publication Number Publication Date
JP2007527850A JP2007527850A (ja) 2007-10-04
JP2007527850A5 true JP2007527850A5 (https=) 2010-07-01
JP4584908B2 JP4584908B2 (ja) 2010-11-24

Family

ID=33099898

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006500159A Expired - Lifetime JP4584908B2 (ja) 2003-02-12 2004-02-12 皮膚または皮膚付属物の色素沈着を刺激するための１５−ヒドロキシプロスタグランジンデヒドロゲナーゼの阻害剤の使用
JP2010025811A Pending JP2010100659A (ja) 2003-02-12 2010-02-08 皮膚または皮膚付属物の色素沈着を刺激するための１５−ヒドロキシプロスタグランジンデヒドロゲナーゼの阻害剤の使用
JP2013269231A Expired - Fee Related JP5897539B2 (ja) 2003-02-12 2013-12-26 皮膚または皮膚付属物の色素沈着を刺激するための１５−ヒドロキシプロスタグランジンデヒドロゲナーゼの阻害剤の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010025811A Pending JP2010100659A (ja) 2003-02-12 2010-02-08 皮膚または皮膚付属物の色素沈着を刺激するための１５−ヒドロキシプロスタグランジンデヒドロゲナーゼの阻害剤の使用
JP2013269231A Expired - Fee Related JP5897539B2 (ja) 2003-02-12 2013-12-26 皮膚または皮膚付属物の色素沈着を刺激するための１５−ヒドロキシプロスタグランジンデヒドロゲナーゼの阻害剤の使用

Country Status (5)

Country Link
US (2) US7705041B2 (https=)
EP (1) EP1594438B1 (https=)
JP (3) JP4584908B2 (https=)
CA (1) CA2515440A1 (https=)
WO (1) WO2004073594A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320967B2 (en) * 2002-04-23 2008-01-22 L'oreal Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair
FR2845000B1 (fr) * 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
EP1594438B1 (fr) * 2003-02-12 2013-07-17 L'Oréal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères
FR2881427A1 (fr) * 2005-01-31 2006-08-04 Oreal Derives de 3-sulfanylpropanamide, composition les contenant et leur utilisation pour stimuler la pousse des cheveux et des cils et/ou freiner leur chute et/ou limiter leur depigmentation
WO2006079568A2 (en) * 2005-01-31 2006-08-03 L'oreal Use of 3-sulfanylpropanamide derivatives for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof
WO2006089076A2 (en) 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
US7863460B2 (en) * 2005-02-25 2011-01-04 Sagami Chemical Research Center Process for producing 1-substituted-3-fluoroalkylpyrazole-4-carboxylate
PE20070404A1 (es) 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
US20070077215A1 (en) * 2005-10-05 2007-04-05 L'oreal Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening
FR2891457B1 (fr) * 2005-10-05 2007-11-23 Oreal Utilisation de composes phenyl-furyl-methyl-thiazolidine-2,4 dione ou phenyl-thienyl-methyl-thiazolidine-2,4-diones pour favoriser et/ou induire et/ou stimuler la pigmentation des matieres keratiniques et/ou limiter leur depigmentation et/
JP2007197352A (ja) * 2006-01-25 2007-08-09 Kameda Seika Co Ltd メラニン産生促進剤
US7666912B2 (en) * 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
US20100074857A1 (en) * 2008-09-23 2010-03-25 Pamela Lipkin Compositions and methods to treat epithelial-related conditions
FR2924931B1 (fr) * 2007-12-12 2010-01-15 Oreal Utilisations de derives 1-°(1h-pyrazol-4-y!heterocycliques pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute ; nouveaux composes ; compositions les contenant.
CN101965176B (zh) * 2008-02-08 2012-06-20 株式会社资生堂 美白剂和皮肤外用剂
WO2010018438A2 (en) * 2008-08-11 2010-02-18 Hetero Research Foundation Tetrazole glycosides
FR2941150B1 (fr) 2009-01-16 2013-01-11 Oreal Produit pour la prevention ou le traitement du blanchissement des cheveux.
JP5530875B2 (ja) * 2009-09-28 2014-06-25 富士フイルム株式会社 メラニン産生抑制剤
FR2951938B1 (fr) 2009-10-30 2012-01-06 Oreal Utilisation d'un extrait de punica granatum pour lutter contre la canitie
AU2010336027A1 (en) * 2009-12-23 2012-07-19 Auckland Uniservices Limited Compounds, preparations and uses thereof
US9139575B2 (en) 2010-04-13 2015-09-22 The Regents Of The University Of California Broad spectrum antiviral and antiparasitic agents
US8859616B2 (en) * 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
US9289365B2 (en) * 2011-10-24 2016-03-22 Avon Products, Inc. Compositions and methods for stimulating collagen synthesis in the skin
DK2838533T3 (da) 2012-04-16 2017-11-27 Univ Case Western Reserve Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
CN118059093A (zh) 2015-03-08 2024-05-24 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
CA3031091A1 (en) 2016-07-18 2018-01-25 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death
KR102146509B1 (ko) * 2017-07-05 2020-08-20 한국화학연구원 피부 미백용 조성물
CA3125900A1 (en) 2019-01-08 2020-07-16 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitor
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors
AU2023301386A1 (en) * 2022-07-01 2025-01-23 Acrotech Biopharma Inc. Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
WO2024154979A2 (ko) * 2023-01-20 2024-07-25 주식회사 이노보테라퓨틱스 신규한 헤테로사이클릭 화합물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565983A (en) * 1896-08-18 August s
SE8405924L (sv) 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
US5653983A (en) * 1991-07-19 1997-08-05 Lvmh Recherche Compositions for the pigmentation of the skin or of the hair containing an extract of Marrubium vulgare, the process for it's manufacture and it's
FR2684300B1 (fr) * 1991-11-29 1994-03-11 Lvmh Recherche Composition cosmetique ou pharmaceutique, notamment dermatologique, destinee en particulier a favoriser la pigmentation de la peau ou des cheveux, contenant un extrait de ballote, et son procede de fabrication.
US5320861A (en) * 1992-01-03 1994-06-14 Ocean Spray Cranberries, Inc. Fruit extraction and infusion
ATE209887T1 (de) * 1993-04-02 2001-12-15 Anticancer Inc Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
SE9303444D0 (sv) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
EP0812210A4 (en) * 1995-02-23 1998-08-19 Life Medical Sciences Inc COMPOSITIONS AND METHODS FOR INCREASING HAIR GROWTH AND MAINTAINING THE HAIR COLOR
WO1998000100A1 (en) * 1996-07-03 1998-01-08 The Board Of Regents Of The University Of Oklahoma Enhancement of skin pigmentation by prostaglandins
EP0884045A1 (en) * 1997-06-06 1998-12-16 Pfizer Products Inc. Self-tanning dihydroxyacetone formulations having improved stability and providing enhanced delivery
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
AU742787B2 (en) * 1997-07-09 2002-01-10 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
US6267948B1 (en) 1998-04-06 2001-07-31 Applied Genetics Incorporated Dermatics Dermatological formulations and methods
EP1214038A2 (en) * 1999-09-09 2002-06-19 Androsolutions, Inc. Methods and compositions for preventing and treating prostate disorders
FR2807323A1 (fr) * 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
US20050042674A9 (en) * 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
CA2482711A1 (fr) * 2002-04-23 2003-11-06 L'oreal Composition cosmetique pour favoriser la pousse et/ou empecher ou retarder la chute des cheveux
FR2838641B1 (fr) * 2002-04-23 2005-12-23 Oreal Composition cosmetique, procede de traitement cosmetique et preparation d'une composition pour favoriser la pousse et/ou empecher ou retarder la chute des cheveux
FR2845000B1 (fr) 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
EP1594438B1 (fr) * 2003-02-12 2013-07-17 L'Oréal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity

Similar Documents

Publication Publication Date Title
JP2007527850A5 (https=)
JP4619531B2 (ja) Ｆｐアゴニストとして有用な、芳香族のあるｃ１６〜ｃ２０が置換されたテトラヒドロプロスタグランジン類
AU741014B2 (en) Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists
USRE43372E1 (en) C16 unsaturated FP-selective prostaglandins analogs
JP6149975B2 (ja) 二環式化合物およびその医薬用途
EP1012136B1 (en) Aromatic c 16?-c 20?-substituted tetrahydro prostaglandins useful as fp agonists
JP2014502974A5 (https=)
JP5835236B2 (ja) 二環式化合物およびその医薬用途
CA2364944C (en) C16 unsaturated fp-selective prostaglandins analogs
CA2324343C (en) C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
CA2324590C (en) C11 oxymyl and hydroxylamino prostaglandins useful as fp agonists
MXPA00002433A (en) Aromatic c16
CZ2000848A3 (cs) Sloučenina analogická prostaglandinu F a její použití